Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. (Q37103086)
Jump to navigation
Jump to search
scientific article published on December 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. |
scientific article published on December 2008 |
Statements
1 reference
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. (English)
1 reference
Edith A Perez
1 reference
Wilma L Lingle
1 reference
Alvaro Moreno-Aspitia
1 reference
Roscoe F Morton
1 reference
David W Hillman
1 reference
Kendrith M Rowland
1 reference
Martin Wiesenfeld
1 reference
Patrick J Flynn
1 reference
Tom R Fitch
1 reference
1 reference
Identifiers
1 reference